Leading investigators and clinicians detail the different
mechanisms used by tumors to escape and impair the immune system
and then spell out possible clinical strategies to prevent or
reverse tumor-induced immune dysfunction. The authors review the
mechanisms of immune dysfunction and evasion mechanisms in
histologically diverse human tumors, focusing on tumor-induced
molecular defects in T cells and antigen-presenting cells
(dendritic cells and tumors), that may serve as biomarkers for
patient prognosis. They discuss the means by which these immune
functions may be protected or restored in order to more effectively
support the process of tumor rejection in situ. Cutting-edge
techniques are outlined with the capacity to monitor the strength
and quality of patients' immune responses using immunocytometry,
MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay,
and detection of MHC-TAA peptide complexes on tumor cells.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!